In brief: Cytopia; LCT; Rockeby
Thursday, 10 March, 2005
Cytopia (ASX:CYT) today filed an Investigational New Drug Application with the US Food and Drug Administration, seeking approval to test its cancer drug candidate CYT997 in the clinic.
Rockeby biomed (ASX:RBY) has announced the resignation of Dr John Warmington as the company's director of research and development. Warmington assume a consultancy role with the company as chief scientist. Dr David Capes will take up the position of vice president of research and development.
Xenotransplantation company Living Cell Technologies (ASX: LCT) has appointed Paris Brooke as general manager. Brooke was formerly policy and communication manager at AusBiotech.
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
